GIULIO DRAETTA to Proto-Oncogene Proteins p21(ras)
This is a "connection" page, showing publications GIULIO DRAETTA has written about Proto-Oncogene Proteins p21(ras).
Connection Strength
1.278
-
The KRAS mutational spectrum and its clinical implications in pancreatic cancer. Cancer Cell. 2024 Sep 09; 42(9):1494-1496.
Score: 0.585
-
Genetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic cancer. Cancer Res. 2015 Mar 15; 75(6):1091-101.
Score: 0.303
-
Predictive Signatures Inform the Effective Repurposing of Decitabine to Treat KRAS-Dependent Pancreatic Ductal Adenocarcinoma. Cancer Res. 2019 Nov 01; 79(21):5612-5625.
Score: 0.104
-
Syndecan 1 is a critical mediator of macropinocytosis in pancreatic cancer. Nature. 2019 04; 568(7752):410-414.
Score: 0.100
-
Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Nature. 2014 Oct 30; 514(7524):628-32.
Score: 0.073
-
Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic cancer. Cell. 2014 Jul 03; 158(1):185-197.
Score: 0.072
-
Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer. Nature. 2017 02 16; 542(7641):362-366.
Score: 0.022
-
Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev. 2016 Feb 15; 30(4):355-85.
Score: 0.020